INTRODUCTION AND OBJECTIVES: Although radical prostatectomy (RP) has been proposed as a feasible and effective therapeutic approach in prostate cancer (PCa) patients with enlarged lymph nodes at imaging (cN1), no data are available on the long-term outcomes and patterns of recurrence of surgically managed patients with cN1 disease.
INTRODUCTION AND OBJECTIVES: Although radical prostatectomy (RP) has been proposed as a feasible and effective therapeutic approach in prostate cancer (PCa) patients with enlarged lymph nodes at imaging (cN1), no data are available on the long-term outcomes and patterns of recurrence of surgically managed patients with cN1 disease.
METHODS: Overall, 149 patients with lymphadenopathies in the pelvis and/or retroperitoneum detected by CT scan (n[92; 61.7%) or MRI (n[57; 38.3%) treated with RP and nodal dissection between 2005 and 2013 with at least 5 years of follow-up were identified. Clinical recurrence (CR) was defined as the onset of metastases. The site of the first CR was stratified as: local (i.e., prostatic fossa and regional nodes), retroperitoneal and distant (i.e., bone and visceral metastases). Cox regression analyses assessed predictors of distant metastases after adjusting for adjuvant treatments. Poisson smoothed cumulative incidence plots assessed 10-year cancer-specific mortality (CSM) and other cause mortality (OCM) after stratifying patients according to predicted risk of 8-year distant metastases.
RESULTS: Median number and size of lymphadenopathies were 1 and 14 mm and 25 (20%) patients had retroperitoneal involvement. The median number of positive nodes was 7 and 117 (78%) patients had lymph node invasion. Median follow-up was 86 months. Overall, 91 (61%) patients received adjuvant hormonal therapy. Overall, 53, 30 and 11 patients had CR, CSM and OCM. The 10-year CR-free rates were 56 and 78%. Overall, 11 vs. 6 vs. 21% patients had local vs. retroperitoneal vs. distant CR. The 10-year CSM-free rates were 66 vs. 62 vs. 44% for local vs. retroperitoneal vs. distant CR. Grade group 4-5 and retroperitoneal involvement were associated with distant CR (P 0.01). At 10-year, 21 and 7% patients experienced CSM and OCM. The risk of dying from OCM was the same as CSM in patients with a 8-year distant metastases probability <15%. Conversely, 34 vs. 5% patients died from PCa vs. OCM among men with a risk !15%.
CONCLUSIONS: Although the risk of CSM was overall higher than OCM, in men with an estimated risk of distant metastases <15% the risk of CSM did not exceed the risk of OCM. These findings have important implication for patient selection and for the administration of timely salvage therapies at recurrence.
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MP22-17 BIOCHEMICHAL RECURRENCE IN PROSTATE CANCER AFTER SALVAGE SURGERY IN CORRELATION TO THE SITE OF RECCURRENT DISEASE
David Pfister*, Yasmin Pullankavumkal, Friederike Haidl, Cologne, Germany INTRODUCTION AND OBJECTIVES: Due to improved diagnostic tools salvage surgery is getting more popular after failure of primary local treatment as radical prostatectomy or radiotherapy. We analyzed PSA progression free survival (PFS) after radical prostatectomy and or radiotherapy in accordance to the location of the recurrence and the performed salvage surgery.
METHODS: We retrospectively analyzed 274 patients with salvage surgeries. 142, 18, and 114 patients underwent salvage radical prostatectomy (SPRE, Group1), locoregional recurrences mainly in seminal vesical remnants (SVR, Group2) or salvage lymph node dissection (SLND, Group3). All patients were diagnosed either by Choline-or more lately PSMA-PET CT. All surgeries had been done open. In Group1 radical prostatectomy and lymph node dissection, in Group 2 the seminal vesicals and in Group3 an ipsilateral pelvic lymph node dissection had been performed due to imaging results.
RESULTS: Median age at time of surgery was 67(62-72)years. Median PSA was 3.1(1.45-5.45)ng/ml. Radiotherapy or hormone therapy before salvage surgery in Group 1,2,3 was done in 100%, 61,1%, 54,39% and 12,6%, 27,8%, 18,42% of the patients. Median progression free survival in Group 1, 2, 3 is 41(11.104), 29 (8-47) and 8 (2-21) months (p<0.001). PSA PFS in Group1/2 and Group 1/3 differed significantly with an HR of 1.85 (95%CI;1,0-3.44) and HR of 2.72 (95% CI; 1,84-4,04). Only age at time of surgery and interval from primary treatment to salvage procedure in months were significant predictors in an univariate Cox regression analysis.
CONCLUSIONS: We demonstrate that the best biochemical control in salvage surgeries is achieved in patients with isolated recurrence in the prostate after radiotherapy. The effect of salvage surgery decreases with increasing distance of the site of recurrence to the prostate. METHODS: Eudra-Vigilance database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). We explored the effect of age on AES in patients treated with AAP, ENZ and Radium223. Patients were divided in three groups classified by age: 85 yo, between 65 and 85 and <65 yo. Pooled Relative Risk (PRR) were used to compare groups.
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RESULTS: Data from Eudra Vigilance indicates that AA, Radium and ENZ treatment is well tolerated with few significant differences in the different age groups. Particularly, patients with age between 65 and 85 years old treated with AAP had a statistically significant higher risk of cardiac and metabolism disorders while a lower risk of musculoskeletal, hepatobiliary and connective tissue diseases Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e323
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